Pharmacia Ab

Pharmacia & Upjohn Ab

Pfizer Health Ab

Helle Kristensen

Ulla Hoeck

Lene Orup Jacobsen

Bo Kreilgard

Birgitta Olsson

Lisbeth Nilvebrant

Martin Wikberg

Anders Ringberg

Torkel Gren

Bengt Hall&eacute;n

Jan Str&ouml;mbom

Bo Kreilgaard

Bo Kreilg&aring;rd

Jan Strömbom

Bo Kreilgård

Bengt Hallén

The present invention is drawn to set of formulations of at least one compound selected from tolterodine, salts thereof, prodrugs thereof and/or metabolites thereof, wherein in the set of formulations contains at least one device for transdermal administration and at least one formulation for oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transmucosal administration, in order to achieve an effect against overactive bladder and/or symptoms associated with this condition. The present invention is further drawn to methods of treating an overactive bladder with the formulations.

Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder

The present invention is drawn to a method of treating an unstable or overactive urinary bladder by treating the patient with tolterodine or a tolterodine-related compound, or pharmaceutically acceptable salt thereof, with a controlled release formulation that maintains a substantially constant serum level of the active moiety or moieties for at least 24 hours. The present invention is further drawn to a formulation for the method.

Therapeutic formulation for administering tolterodine with controlled release

Device for transdermal administration of tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, optionally together with pharmaceutically acceptable carrier(s) to a human being or an animal in order to achieve an effect against overactive bladder. Use of a compound having an effect against overactive bladder comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s), for the manufacture of a composition to be administered transdermally for achieving an effect against overactive bladder. Method for achieving an effect against overactive bladder in a living body by transdermal administration of a compound comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s).

The present invention is drawn to a device for the transdermal administration of dextromethorphan, (&plus;)-3-methoxy-17-methyl-9a,13a,14a-morphanin, and salts, prodrugs and metabolites thereof, together with a pharmaceutically acceptable carrier, to a human being or animal in need thereof, to achieve an antitussive effect. The present invention is further drawn to a method of achieving an antitussive effect in a human being or animal which comprises transdermally administering dextromethorphan, (&plus;)-3-methoxy-17-methyl-9a,13a,14a-morphanin, and salts, prodrugs and metabolites thereof, together with a pharmaceutically acceptable carrier.

Transdermally administered dextromethorphan as antitussive agent

Growing community of inventors

Slangerup, Denmark

Helle Kristensen